Overview

Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
0
Participant gender:
All
Summary
Primary Objectives: 1. To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma. 2. To compare the pharmacokinetics and pharmacodynamics of curcumin and curcumin + Bioperine and evaluate the effect of Bioperine on the bioavailability of curcumin. 3. To evaluate the biologic effects of curcumin alone and in combination with Bioperine on the expression of NF-kB and related genes in the Multiple Myeloma (MM) cells.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Curcumin
Criteria
Inclusion Criteria:

- Patients with multiple myeloma who have been previously untreated, are asymptomatic
and without serious or imminent complications; or have relapsed or failed treatment
with conventional therapy.

- Adequate hematologic, renal, and hepatic functions.

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

Exclusion Criteria:

- Previously untreated patients with high tumor mass; symptomatic or impending
fractures.

- Patients with significant cardiac disease.

- Patients with comorbid condition which renders patients at high risk of treatment
complications.

- History of significant neurological or psychiatric disorders.